DrugPatentWatch Database Preview

Details for Patent: 8,410,167

Which drugs does patent 8,410,167 protect, and when does it expire?

Patent 8,410,167 protects MULTAQ and is included in one NDA.

This patent has fifty-four patent family members in twenty-seven countries.

Summary for Patent: 8,410,167

Title:	Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality
Abstract:	Methods of using dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality, articles of manufacture and packages related thereto.
Inventor(s):	Radzik; Davide (Paris, FR), Van Eickels; Martin (Berlin, DE), Hamdani; Nacera (Paris, FR), Gaudin; Christophe (Paris, FR)
Assignee:	SANOFI (Paris, FR)
Application Number:	12/425,125
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,410,167
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 8,410,167

Glossary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Sanofi Aventis Us	MULTAQ	dronedarone hydrochloride	TABLET;ORAL	022425-001	Jul 1, 2009		RX	Yes	Yes	➤ Sign Up	➤ Sign Up				TREATMENT OF PATIENTS WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF WITHOUT SEVERE HEART FAILURE AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS	➤ Sign Up
Sanofi Aventis Us	MULTAQ	dronedarone hydrochloride	TABLET;ORAL	022425-001	Jul 1, 2009		RX	Yes	Yes	➤ Sign Up	➤ Sign Up				REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF WITHOUT SEVERE HEART FAILURE AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAILY WITH MORNING AND EVENING MEALS	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted

Foreign Priority and PCT Information for Patent: 8,410,167

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
France	08 02127	Apr 17, 2008
France	08 03208	Jun 10, 2008
	09290095	Feb 11, 2009
	09290098	Feb 11, 2009

Non-Orange Book US Patents Family Members for Patent 8,410,167

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Patent No.	Title	Estimated Patent Expiration
9,107,900	Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of morality	➤ Sign Up
Patent No.	Title	Estimated Patent Expiration

International Family Members for US Patent 8,410,167

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Ukraine	108980	➤ Sign Up
Taiwan	201529068	➤ Sign Up
Taiwan	200946108	➤ Sign Up
Taiwan	I519298	➤ Sign Up
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration

Summary for Patent: 8,410,167

Foreign Priority and PCT Information for Patent: 8,410,167

For more information try a trial or see the plans and pricing